With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Ascribing benefits to the experience of devastating illness or trauma is fraught with hidden dangers.
New types of biological filaments are turning up in yeast, fly, bacterial cells and in rat neurons, and they may yield clues to how the cytoskeleton evolved from metabolically active enzymes.
August 1, 2011
Meet some of the people featured in the August 2011 issue of The Scientist.
A guide to free software for constructing and assessing species relationships
To ensure high-quality clinical trials of a malaria vaccine, organizers in rural Africa must first upgrade electrical and research infrastructures.
Gut bacteria may be the missing piece that explains the connection between diet and cancer risk.